MF PHARMA
Sources: the KBO register on 22-11-2026; the National Bank, 2025 annual accounts filed on 14-04-2026; the Belgian Official Gazette, latest deed of 25-03-2026.
Grounds
the facts the verdict rests on, each with its source- MF PHARMA made a profit in every financial year since 2022.Annual accounts 2022 to 2025 page 2
- Equity stands at €15,747, or 16.4% of the balance sheet total of €96,029. The solvency of 16.4% is higher than at 35% of the 25,428 companies filing micro accounts in retail trade (NACE 47) in 2025.Annual accounts 2025 page 2
- MF PHARMA paid out €90,000 in dividends, 261% of the profit of 2025. Because of the dividend and €55,549 higher other debts due within one year, solvency fell from 73.3% to 16.4%.Annual accounts 2025 page 2
- The last four annual accounts came in on time. The 2025 accounts were filed 108 days before the end of the term.National Bank, filing of 14-04-2026 page 4
Representation
The signing rule is in the founding deed of 07-09-2022.
Articles of association, Belgian Official Gazette of 07-09-2022, deed 22355997
Ownership
The accounts in the micro format list no shareholders. holds all 100 shares.
Deed of 07-09-2022
Financial situation
Annual accounts 2022 to 2025, as filed with the National Bank
Gross margin and net resultin euro
Equity and debtsin euro
Cashin euro
| Financial year | 20223 months | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|---|
| Results | |||||
| Gross margin | €8,811 | €39,410 | €58,808 | €55,691 | |
| Operating result | €8,761 | €31,362 | €50,603 | €47,968 | |
| Net result | €6,944 | €23,979 | €39,953 | €34,505 | |
| Balance sheet at the closing date | |||||
| Equity | €8,144 | €31,290 | €71,242 | €15,747 | |
| Debts | €7,172 | €32,595 | €25,923 | €80,282 | |
| Debts due after more than one year | - | €6,882 | €1,754 | - | |
| Debts due within one year | €7,172 | €25,713 | €24,169 | €80,282 | |
| Cash | €7,330 | €37,381 | €79,493 | €74,094 | |
| Balance sheet total | €15,316 | €63,885 | €97,165 | €96,029 | |
| Ratios | |||||
| Solvency | 53.2% | 49.0% | 73.3% | 16.4% | |
| Liquidity | 2.14 | 1.81 | 3.62 | 1.17 | |
Source: Annual accounts 2025, micro format, filed on 14-04-2026 (2026-00080257); Annual accounts 2024, micro format, filed on 10-07-2025 (2025-00256372); Annual accounts 2022 to 2023, filed from 11-07-2023 to 10-07-2024 (2023-00229938, 2024-00250739).
Debts rose by €54,360 in 2025, of which €564 to suppliers. A dividend stands among the debts on the balance sheet date until it is paid.
The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.
MF PHARMA states no turnover; the micro format does not require it. The gross margin, what is left after purchases, fell from €58,808 to €55,691.
The financial year to 31-12-2022 ran for 3 months.
Board, signature and ownership
Position on 22-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts
Who represents the company
The signing rule is in the founding deed of 07-09-2022.
Articles of association, Belgian Official Gazette of 07-09-2022, deed 22355997
Board
one director in officeOwnership and group
Shareholders
The accounts in the micro format list no shareholders. holds all 100 shares.
Deed of 07-09-2022
Events and comparison
The last 24 months, newest first
Annual accounts 2025 filed, 108 days before the deadline.
NBB filingRegistered office moved from Liège to LIEGE Quai de Rome. The registered office moved from Au pèrî 24-4000 LIEGE to 4000 LIEGE Quai de Rome 48/51. Board meeting of 03-03-2026.
Gazette, deed 26042229Annual accounts 2024 filed, 21 days before the deadline.
NBB filingHighest result from 2022 to 2025. The operating result of €50,603 and the net result of €39,953 are both a record.
FinancialComparable companies, two years later
In July 2024, 7,983 companies had the same profile as MF PHARMA has now: micro, 2 to 5 years old, solvency 10 to 30% and a profit of 5% of the balance sheet or more. Two years later 94.3% were still trading, 2.0% had stopped another way and 3.7% had gone bankrupt.
The return on assets of MF PHARMA, 35.9%, is higher than at 94% of the 24,617 companies filing micro accounts in retail trade (NACE 47) in 2025.
Other findings
Peppol
Reachable for e-invoices since 23-10-2025, under 0208:0790439043.
Sanctions lists
Sources and method
Where each fact in this report comes from
| Source | What | Date | Reference |
|---|---|---|---|
| KBO register | Registration, legal situation, activity, establishment units | 22-11-2026 | KBO 0790.439.043 |
| National Bank of Belgium | Annual accounts 2025, micro format | 14-04-2026 | 2026-00080257 |
| National Bank of Belgium | Annual accounts 2024, micro format | 10-07-2025 | 2025-00256372 |
| National Bank of Belgium | Annual accounts 2022 to 2023 | 11-07-2023 to 10-07-2024 | 2023-00229938, 2024-00250739 |
| Belgian Official Gazette | Founding deed with the articles of association | 07-09-2022 | deed 22355997 |
| Peppol Directory | Registration for e-invoices | 23-10-2025 | 0208:0790439043 |
| Sanctions lists EU, UN, US (OFAC) and UK | Comparison of the name | 19-11-2026 | |
| Checked | Checked score, bankruptcy probability, credit, comparable companies | 21-11-2026 | bankruptcy model of 21 November 2026 |
Method
Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.
Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 21 November 2026, computed on 21-11-2026.
Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.
Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.
The scores and ratios are Checked's own calculations, not a credit decision.